Clinical Trial Update: A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

Phase 3 study comparing atezolizumab plus tiragolumab versus durvalumab in locally advanced, unresectable stage III non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Tecentriq (atezolizumab)
• Tiragolumab (tiragolumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Status: COMPLETED